Measles (Rubeola) virus IgM antibody

Bacterial/ Viral

Report in 48Hrs

At Home

No Fasting Required

Details

Detects antibodies to measles virus.

₹1,924₹2,749

30% OFF

Measles (Rubeola) Virus IgM Antibody Test

Why is it done?
- Test Purpose: Detects IgM antibodies against measles virus to identify acute or recent measles infection
- Primary Indications: Diagnosis of acute measles infection in patients with characteristic symptoms (fever, cough, coryza, conjunctivitis, and rash)
- Clinical Symptoms Present: Suspected measles cases presenting with fever, rash, and respiratory symptoms
- Optimal Timing: Best performed 3-5 days after symptom onset through 2-3 weeks after rash appearance (peak IgM response)
- Public Health Purposes: Confirmation for reportable disease surveillance and contact tracing
- Differential Diagnosis: To distinguish measles from other rash-causing illnesses such as rubella, chickenpox, or drug reactions
Normal Range
- Result Interpretation - Negative: <0.8 index or <1:10 titer (depends on laboratory method)
- Result Interpretation - Positive: ≥0.9 index or ≥1:10 titer (indicates acute or recent infection)
- Borderline/Equivocal: Results in gray zone (0.8-0.9 index); repeat testing in 1-2 weeks may be recommended
- Units of Measurement: Index (arbitrary units), titer ratio (1:10, 1:20, etc.), or signal-to-cutoff ratio depending on test methodology (ELISA, immunofluorescence, or chemiluminescence)
- Normal Meaning: Absence of IgM antibodies suggests no acute measles infection at time of testing; may indicate immunity from prior vaccination or infection
- Abnormal Meaning: Presence of IgM antibodies confirms acute measles infection (typically indicates active infection or very recent exposure)
Interpretation
- Positive IgM Result: Confirms acute measles infection; patient is currently infected and highly contagious. IgM appears first in immune response (within 3-5 days of symptom onset) and gradually declines over 1-2 months
- Negative IgM with IgG Positive: Indicates past infection or successful vaccination; confers immunity to measles
- Negative IgM with Negative IgG: No immunity to measles; patient susceptible to infection (vaccine candidate if age-appropriate)
- Early Infection Testing: If tested before day 3 of symptom onset, IgM may be negative even with active infection; consider retesting or using alternative methods (viral culture, RT-PCR)
- Late Infection Testing: If tested >3 weeks after rash onset, IgM may have declined significantly; may appear falsely negative in very recent past infections
- Factors Affecting Results: Timing of sample collection, immunocompromised status (may produce weak antibody response), recent blood transfusions (may contain maternal antibodies in infants), laboratory methodology variations
- Clinical Significance in Timeline: IgM typically appears within 1 week of symptom onset, peaks at 1-2 weeks, and disappears by 6-8 weeks. Persistence of IgM beyond 3 months suggests either chronic infection or test inaccuracy
- Cross-Reactivity Considerations: Minimal cross-reactivity with rubella or other paramyxoviruses in modern assays; confirmed by specificity testing when indicated
Associated Organs
- Primary Organ System: Respiratory system (lungs, bronchi); immune system (lymph nodes, spleen); skin
- Diagnostic Conditions: Rubeola (measles) - highly contagious viral infection; differentiation from rubella (German measles), varicella, scarlet fever, and roseola infantum
- Respiratory Manifestations: Pneumonia, bronchitis, croup; can lead to respiratory compromise in severe cases
- Neurological Complications: Subacute sclerosing panencephalitis (SSPE) - rare, fatal degenerative brain disease occurring years after infection; febrile seizures during acute infection
- Gastrointestinal Involvement: Diarrhea, abdominal discomfort; rarely hepatitis
- Ocular Involvement: Conjunctivitis, keratitis, temporary blindness in severe cases
- Immune System Effects: Temporary immunosuppression, increased susceptibility to secondary infections, lymphoid tissue hyperplasia
- Potential Complications: Encephalitis, meningitis, myocarditis, severe pneumonia, otitis media, secondary bacterial infections, miscarriage if infection occurs in pregnancy
- High-Risk Populations: Immunocompromised individuals, infants <1 year old, pregnant women, unvaccinated populations, malnutrition cases (increased severity)
Follow-up Tests
- Measles IgG Antibody: To confirm immunity after acute infection resolves or to assess immune status from prior vaccination
- Repeat IgM Testing: If initial test is negative but clinical suspicion remains high, retest 1-2 weeks later when IgM levels may increase
- Measles RT-PCR: Viral nucleic acid testing for early detection (within first 3 days of rash); gold standard for early infection confirmation; performed on respiratory specimens or blood
- Viral Culture: Recovery of measles virus from respiratory secretions, urine, or blood; performed in specialized laboratories; slower than PCR but confirmatory
- Direct Fluorescent Antibody Staining: Rapid detection of measles antigen in respiratory specimens during acute infection phase
- Complete Blood Count (CBC): To assess for complications, secondary infections, or immune system status; may show lymphopenia in acute infection
- Liver Function Tests: If hepatitis suspected or if prolonged illness; to rule out hepatic involvement or complications
- Chest X-Ray: If pneumonia suspected; to evaluate extent of respiratory involvement and secondary infections
- Lumbar Puncture with CSF Analysis: If neurological symptoms present (fever with altered mental status, seizures); to rule out encephalitis or meningitis
- Testing for Secondary Infections: Bacterial culture if otitis media, pneumonia, or skin infection suspected; repeat CBC if fever persists
- Immunoglobulin Testing: Immunodeficiency screening if patient has severe or atypical measles presentation
- Monitoring Frequency: For uncomplicated cases, clinical follow-up as symptoms resolve; for complicated cases, follow-up testing depends on specific complications; close contacts should be tested/observed for 21 days post-exposure
Fasting Required?
- Fasting Status: NO - Fasting is not required for measles IgM antibody testing
- Sample Collection: Serum blood sample collected by venipuncture; can be drawn at any time of day regardless of food or fluid intake
- Medications: No medications need to be discontinued; can continue all regular medications including antivirals or immunosuppressants
- Patient Preparation: Minimal preparation needed; inform patient that test is a simple blood draw; can be performed in ambulatory settings, clinics, or hospitals
- Timing Considerations: Sample should be collected as soon as clinically feasible (ideally within 3-5 days of symptom onset); timing is more important than fasting status
- Special Instructions: Wear appropriate personal protective equipment (PPE) when drawing blood from suspected measles patients due to airborne transmission risk; handle sample with standard precautions; label specimen clearly with patient identifying information and collection date/time

How our test process works!